SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cistron Biotechnology(CIST)$.30

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Walter Morton who wrote (2335)6/22/1999 11:25:00 PM
From: John Metcalf  Read Replies (2) of 2742
 
Hi, Walter. No and no.

They bought the stock back $.10 below its current value. They've already made money and don't need a higher share price to get even. Grausz' stock went out at $.2274, and the current bid is $.32.

They reduced the share count, so that the current value of cash and equivalents is $.58 per share.

They were NOT suing Grausz. They had done so, and had won a judgement. However, Grausz filed bankruptcy, and CIST may never be paid. So what! The judgement is a penny per share, and Grausz was hung over the gunwale and sc**wed today, in the amount of $450,000 discount to market. IMHO, he deserved it. Do it again; wait till I get the camcorder out! (It is possible his creditors will get the proceeds from this transaction -- right on again!)

Lots of companies, Ariad for example, will be kicking themselves because they could have had Cistron's cash at par (paid in shares) rather than the toxic convertible private placements they have made.

I expect Cistron to go out well above 58 cents, sometime in 1999.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext